{"name":"Biohaven Therapeutics Ltd.","slug":"biohaven-therapeutics-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"BHV-2100","genericName":"BHV-2100","slug":"bhv-2100","indication":"Migraine prevention","status":"phase_2"},{"name":"BHV-4157","genericName":"BHV-4157","slug":"bhv-4157","indication":"Acute migraine treatment","status":"phase_3"},{"name":"BHV-7000","genericName":"BHV-7000","slug":"bhv-7000","indication":"Migraine prevention","status":"phase_2"},{"name":"BHV-8000","genericName":"BHV-8000","slug":"bhv-8000","indication":"Migraine prevention","status":"phase_2"}]}],"pipeline":[{"name":"BHV-2100","genericName":"BHV-2100","slug":"bhv-2100","phase":"phase_2","mechanism":"BHV-2100 is a calcitonin gene-related peptide receptor antagonist.","indications":["Migraine prevention"],"catalyst":""},{"name":"BHV-4157","genericName":"BHV-4157","slug":"bhv-4157","phase":"phase_3","mechanism":"BHV-4157 is a selective serotonin 5-HT1F receptor agonist that reduces neuronal activity and neuropeptide release to treat acute migraine.","indications":["Acute migraine treatment"],"catalyst":""},{"name":"BHV-7000","genericName":"BHV-7000","slug":"bhv-7000","phase":"phase_2","mechanism":"BHV-7000 is a calcitonin gene-related peptide receptor antagonist.","indications":["Migraine prevention"],"catalyst":""},{"name":"BHV-8000","genericName":"BHV-8000","slug":"bhv-8000","phase":"phase_2","mechanism":"BHV-8000 is a calcitonin gene-related peptide receptor antagonist.","indications":["Migraine prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNQWV6MDAzNm9DWHFic1BiaHV5QWQ4emZHYnd5M3JSLU8wVGd0RkZNZTZIVmZKX3ZLY09lQ0Y2alRWTlcwQTU5aThheFFHa2tuV2Zodi1idXd3d3NZY2hnTzZLeVNWaGFVTTRlUTZiSkN1cUNUVXF5cEZIQThyeDhQZVRGekw5TV94Y0trV0JseDZfXzlNa0FVdFF6elg1dXZJUmNhZXBLOERncjVEV0JMdk4xWWt3Y20zSEVqbXUxcXZxOS1oZUlfM0dWWEotS2tPWFU2NnZmTmxHRGlrWTNObTNnYXp6bTBSdEpsU1BuY2lCZTFoUVJqczV0TWtfVm9vQnc?oc=5","date":"2026-02-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Oric Pharmaceuticals (ORIC) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Oric Pharmaceuticals (ORIC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNWGFqUGpkb01sb1hzeWlZZEJNQWIwLV8zWlRKaDNKcVRya09ENXE3MmFEWXpKVGFUa0FacDQ3MTVEaVpiQ19BVHY3X1hoOTlkMWZ3RVB5RmRtU3BrTUhyRXlqX2QwZWRfc0ZBS3o4X1ZyVGplTTREcTFLX19nTnd0MkpucnRLMGxxem0tZF9ySWVWVnNiVjdqcnc0RGVYNURxSF9sNVI3RUVTS2EtZXRLV3kySWhJZnBoS2JQNEVVY214cFduNTFuRnVTbHFSM1BMaU5sYzJPRnhjYzVkTGVKRkRLZHdxTTMtMWJyQzlmYkFJOEVGdmkzeFdLVDNHbm51XzVLTmJ5bm5ybVhWdVM1LXlRNU1QTTFtNUNpT0pNU0ExUjctQVFxYzJ3?oc=5","date":"2026-02-20","type":"regulatory","source":"The Globe and Mail","summary":"Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN), Olema Pharmaceuticals (OLMA) and Hims & Hers Health (HIMS) - The Globe and Mail","headline":"Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (BHVN), Olema Pharmaceuticals (OLMA) and Hims & Hers Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxPN1VFdldSd2RiLXphRFkyamx4a3JkdThBc0hLRlQzbjZfZ29nYnZWQzhqWlV3ZmhWQ1BpMzBOaTNmbTFkemwyR0JaNGQ1Yzl1Tzc3dGpvVWlaQldHZVc4bG5FOXMwTnRmbjZGSWkyTnFJNWN3SXhNVTY0bWd3Ump1ZWhaOUUxS3hmblRTU05zLURBUTMyV2xON1ZHa0FBbDhndm5YSVVjOU9ueG1Ob1E4R3U3WmpCX201VDBwaS12ZUNDcEVjOG5YUjJ5ZmRndFhvQ042bEk5ZG9ZU3RTVDBPTDdGZkxrMWpSQjA5Qk14VlpYelJhTzZCOFFfRjNjTkJSZVN1Q0tzd1BXX2Y2bGllblNFOVhONEdoLXZlRWR6UXl4TWN1RWVSRWk1czBZcE5YZXdRRk03aUZwdkkxUkZEdkoyWXZ2d1NUYXZHSVNRNFg5QQ?oc=5","date":"2026-01-12","type":"trial","source":"PR Newswire","summary":"Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire","headline":"Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Mile","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQYUNfYU9aMURNeUtJenhwVEhvQWVsSnJXcEtNV0tJcFd1MnZneU5YWFNJWHJLQXptRXVCNlBfejdpTzhoMVJLcTF5NWlVejFUQlJ1U2xlQTg1cVk4U2c5MDdkdDJMeUZPSm1tczZsdG9QajNKSnVuSFkwa2dlM3Fkdnk0bjNDLWpEVW94aXZjU1FiQXVw?oc=5","date":"2025-11-05","type":"regulatory","source":"BioPharma Dive","summary":"Knocked back by the FDA, Biohaven turns to major cost cuts - BioPharma Dive","headline":"Knocked back by the FDA, Biohaven turns to major cost cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxONTh3Mkg2aHB1LXluTDRiMzRWbzRuUE9fY0pYUU1tbExITVN6TGdtdW1UN0JOWkFQV2kzM1FQNjZEdU10bHpxbmJBZzB6YnE4WUExcHpYTW1TZGZKSDdFdUtPa1JrdlE3NzRUSmlTVk95dGN1a1l6VXp6dDFWOUx3THBISnlMbWxKWW9wY3NjNng0ZXQ3WGU2TDQzUHJHLWNucVJNblRnMmtjaGNmY1NPUmJHLTJqZmpQWm1XYzZlemN4eVZ1cjVmQzhGY0loLXpWeExpU0ZUay1Sazl3RWVobW84YVYweUJkWG92WGJXbjVpODdRRUlYSDdkYWsyVFI0RGlN?oc=5","date":"2025-11-04","type":"regulatory","source":"PR Newswire","summary":"FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia - PR Newswire","headline":"FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQZFRCeFFpZkp5ZDdSVGZKaWg3aDJNbFlkWkZoTUVqZXZ0QnR1cVhiS3ZnaXRyNVJrRjF4cWJOM3dnZUFSN2ZRUDJZM3NFYzVWLU1NcFpwQ0dEV2NMUnZuM2VFZ2lNQmpjWnhiSmJSR2FTcTdGbTE3bTNGZ2xLT0VOa1ZDVFMzR3lSRVZYb1VvQmoyYk1MS295c3pBd2g3N2hiNmZzUm1sLTd2azRPak1kY0VzTFViYkoyNlZ5SmtXM1c?oc=5","date":"2025-04-28","type":"pipeline","source":"PR Newswire","summary":"Biohaven Announces Investment up to $600 Million by Oberland Capital - PR Newswire","headline":"Biohaven Announces Investment up to $600 Million by Oberland Capital","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-05-29","type":"pipeline","source":"PR Newswire","summary":"Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day - P","headline":"Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunolog","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOdGh2VXphcDVDcUp6QzU5RHBvS3RuZXAya0lMZ3V1aU1rdWZsNmdwN3FSeWxuWnhhYTlWOVdfaEludHUxeHNzdFMwZGtBSi0wOU1IUmZlRGtfQkRPSUZNaGlnMXk1LWpzXzVUZTdFY2JjYTU3b0p3VVhRTXB0cU1RdDR0OGh0MzJNanFJZmNVZHZkTkJNaVJGZGJrelpZeHVIZXl6VDZHODNVbXFiejAwMm92c1FyRm1VNEFzOUR4dE9nWEJNSXZYdHRISmplOEpfdUJIc1dURkpCdw?oc=5","date":"2024-05-09","type":"earnings","source":"PR Newswire","summary":"Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments - PR Newswire","headline":"Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNeUZhS3lEOHRqZ3RpWHdDWmwxemI0VmthZVZQODkzdUtGa2hUMnFMU0lfNWNZbTllQk1laXRxRnFkejVHbkZ1YjJiUmFySjBUY01feTdpZTFWeW83ZXl2SDlOM3hZaXR5eHJEeHM0eG1GRTJWcGx1dnFkNW5aVHEwR3UzSUVDS1FNc1BOcVVfdkJaNXNFREl3YjFvelBrTlRnYThvUW85Y2JhclhB?oc=5","date":"2022-11-09","type":"pipeline","source":"Fierce Biotech","summary":"Biohaven fuels up for post-Pfizer future with $302M fundraising, fresh faces in the C-suite - Fierce Biotech","headline":"Biohaven fuels up for post-Pfizer future with $302M fundraising, fresh faces in the C-suite","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPYXpWbEtNY0x0Y0Ftbnh5SXN1WXl0M1F6eXNKbWtEcEV1UmJBWjhjSEtzRXRLMkd6a1YyRnRfbFl6MlFvTjdNdnRDeHhJTjdiQm5LaGM5d24tZWw5MEdtV0lOYmRta1JXQ1g0V0tGcmhfSG5tdVA0ME1ycWhLUXhqQ01JUjcxSjdQbE5IejRrVlVpdUhzSFVz?oc=5","date":"2022-10-05","type":"pipeline","source":"hartfordbusiness.com","summary":"Pfizer completes Biohaven acquisition, spinoff launched - hartfordbusiness.com","headline":"Pfizer completes Biohaven acquisition, spinoff launched","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQSERQelNaLXZnOHFURWlibzVtdmdXTnhNd3JFaGx5WjhzRXhIOC1lT0Y4YmJBd0pNTm8yRTNVOTY2aC13UW1DM2gzbnRrRGVPdkR3OUxlby1UWjlBeHhNRWM5Ul90YXlkNHZUbGpaVUU4M1R0d0xfV2pXZGNxVWtpVzNNTmtsVXdSUExObjBZakU5SkM2azBlcnVYS1pVXzltbkowZzR5eFUtaF85aXRKcnBISmVRNURjOG1TekluTFA5eF96a2pHZGF4SHZwWmp4Zkg3emJIM0FQUDY1TlZsVDRlcHJqTnV4M3NzaTRRRjJXNmU1YU0weUZIWmFXUE0?oc=5","date":"2021-01-07","type":"deal","source":"PR Newswire","summary":"Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs - PR Newswire","headline":"Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE00WGdlNWNBdDh4NEJ6Z1QwT1NwWG5IWUdqa3dYWkt1SEtkVlowbm11MldiVGFvaFdMMzFQRWJuSTBaTXJPZEIzWHE2MVNoTEtuVEZ2TEZrc3lUVHQyZHJj?oc=5","date":"2020-09-01","type":"pipeline","source":"nature.com","summary":"Biohaven: committed to novel treatments for central nervous system diseases - nature.com","headline":"Biohaven: committed to novel treatments for central nervous system diseases","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}